8,415 Shares in Stryker Co. (NYSE:SYK) Acquired by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC acquired a new stake in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, HoldingsChannel reports. The fund acquired 8,415 shares of the medical technology company’s stock, valued at approximately $3,030,000.

Several other large investors have also made changes to their positions in the company. Norges Bank bought a new stake in shares of Stryker during the 4th quarter worth $1,710,744,000. Raymond James Financial Inc. bought a new stake in shares of Stryker in the 4th quarter valued at approximately $353,394,000. FMR LLC raised its stake in Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after acquiring an additional 727,850 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Stryker by 52,520.8% during the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after purchasing an additional 595,061 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company’s stock worth $1,298,426,000 after buying an additional 420,153 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SYK. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Evercore ISI decreased their target price on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $425.84.

Stryker Price Performance

Shares of SYK opened at $377.77 on Wednesday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market capitalization of $144.19 billion, a PE ratio of 48.68, a PEG ratio of 2.93 and a beta of 0.93. The company’s 50-day moving average is $365.95 and its 200-day moving average is $374.03. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the firm posted $2.50 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Equities analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.